Full
Outline
Interleukin-15 (IL-15) stimulates the proliferation of CD8+ T lymphocytes and activates cytotoxic T lymphocytes, memory CD8+ T cells, and natural killer cells, demonstrating broad application prospects in cancer immunotherapy. The activation of effector cells by IL-15 relies on a unique trans-presentation signaling mechanism. This process involves the initial binding of IL-15 to IL-15 receptor alpha (IL-15Rα) to form the IL-15/IL-15Rα complex, followed by binding of this complex to the IL-15 receptor beta/gamma (IL-15Rβ/γ) on target cells, thus exerting its pharmacological effects. The clinical application of recombinant interleukin-15 (rIL-15) faces challenges including its short half-life time and limited availability of endogenous IL-15 receptor alpha (IL-15Rα). Additionally, the immunosuppressive tumor microenvironment impairs its anti-tumor efficacy. In this study, a recombinant IL-15Rα-sushi-HSA fusion protein (rILR-HSA) is designed and expressed, which comprises the IL-15Rα sushi domain fused to human serum albumin (HSA). The co-hitchhiking drug delivery system, rILR-HSA/BPBBT/rIL-15 nanoparticles, prepared by the hydrophobic binding between the HSA component and the photothermal agent molecule BPBBT, followed by the high-affinity binding between IL-15Rα-sushi and rIL-15. Compared with free rIL-15, rILR-HSA/BPBBT/rIL-15 nanoparticles extend the serum half-life time of rIL-15 by 2.6-fold. Simultaneously, the tumor accumulation of rILR-HSA/BPBBT/rIL-15 nanoparticles in the orthotopic CT26-Luc colon cancer-bearing mice facilitates intraoperative near-infrared window-Ⅱ fluorescence image-guided photothermal immunotherapy. The co-hitchhiking drug delivery strategy employs a fusion protein carrier to co-deliver rIL-15 and photothermal agent, providing an approach for safe and effective IL-15-based photothermal immunotherapy of tumor. Animal experiments were conducted with the approval of the Institutional Animal Care and Use Committee of the School of Pharmacy, Fudan University (ethics number: 2018-09-YJ-LW-01).
333
137
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62662699(Operation and Technical Support)
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
